BullFrog AI and Sygnature Discovery Announce Official Sales Launch of BullFrog Data Networks™ to Global Biopharma Clients

Rhea-AI Summary

BullFrog AI (NASDAQ: BFRG) has officially launched commercial sales of its BullFrog Data Networks™ platform through its partnership with Sygnature Discovery. The launch, which began on September 12, represents a potential $15-30 million revenue opportunity through 2028.

The AI-driven platform, designed for drug development and discovery, will be marketed to Sygnature's global biopharma client base. The platform's capabilities include target identification, mechanism-of-action analysis, patient stratification, drug repurposing, and clinical trial optimization. Sygnature's business development team has completed training to integrate BullFrog Data Networks™ into their drug discovery solutions portfolio.

Positive

• Potential revenue opportunity of $15-30 million through 2028
• Partnership with leading CRO Sygnature Discovery provides access to global biopharma clients
• Successfully completed training of Sygnature's global business development team
• Platform offers multiple applications in drug discovery and development process

Negative

• Revenue projections extend over a long period (through 2028)
• Actual revenue realization depends on successful market adoption

Insights

Biotechnology Investment Analyst

BullFrog AI begins commercializing its data platform via Sygnature partnership, targeting $15-30M revenue through 2028.

This commercial launch represents a critical inflection point for BullFrog AI as it transitions from technology development to revenue generation. The company's BullFrog Data Networks™ platform has now moved beyond the preparation phase into active sales through Sygnature Discovery's established biopharma client network. With Sygnature's business development team fully trained and promoting the platform, BullFrog has created a strategic distribution channel that bypasses the typical challenges of direct enterprise sales cycles in biopharma.

The $15-30 million revenue projection through 2028 provides a concrete financial framework for evaluating this partnership's potential impact. Breaking this down, it suggests approximately $5-10 million in annual revenue potential if evenly distributed, which would be significant for a company at BullFrog's stage. The platform's multiple applications across the drug development pipeline—from target identification to clinical trial optimization—creates multiple entry points for client engagement.

What's particularly notable is that this partnership leverages Sygnature's established relationships to accelerate market penetration without BullFrog having to build an extensive sales organization from scratch. This capital-efficient go-to-market strategy allows BullFrog to focus resources on platform enhancement while generating revenue. The endorsement from Sygnature's CTO also signals confidence in the platform's technical capabilities and market fit within their existing service offerings for drug discovery.

Sales launch marks pivotal commercial milestone, unlocking up to $30 million in potential revenue through 2028

GAITHERSBURG, Md., Sept. 25, 2025 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), a technology-enabled drug development company using artificial intelligence (“AI”) and machine learning to enable the successful development of pharmaceuticals and biologics, today announced that its collaboration with Sygnature Discovery, a leading contract research organization (CRO) specializing in drug discovery, has entered the commercial phase. With the formal sales kickoff on September 12, BullFrog AI’s proprietary BullFrog Data Networks™ platform is now actively being introduced to Sygnature’s global client base, representing a revenue opportunity estimated at $15–$30 million through 2028.

The commercial rollout follows the completion of training for Sygnature’s global business development team, equipping them to market BullFrog Data Networks™ as part of Sygnature’s industry-leading portfolio of drug discovery solutions. By leveraging Sygnature’s extensive relationships across the biopharma sector, BullFrog AI is looking to accelerate adoption of its pioneering platform at scale.

“The official kickoff of sales through Sygnature marks a potential inflection point for BullFrog AI,” said Vin Singh, Founder and CEO of BullFrog AI. “We are now positioned to realize the revenue potential of this collaboration and deliver our AI-driven data insights platform to biopharma innovators globally. Our shared commitment to accelerating drug discovery will create significant value for researchers and patients alike.”

BullFrog Data Networks™ empowers researchers to navigate complex, multi-modal datasets and uncover hidden relationships critical to understanding disease biology. Applications include early target identification, mechanism-of-action elucidation, patient stratification, drug repurposing, and clinical trial optimization, all delivered through a disease-centric, visual, and intuitive interface.

“Our team is excited to offer BullFrog Data Networks to our clients,” said Stuart Onions, Chief Technical Officer at Sygnature Discovery. “The platform strengthens our ability to deliver best-in-class solutions, enabling biopharma researchers to unlock the full potential of their data and improve R&D efficiency.”

About BullFrog AI

BullFrog AI leverages Artificial Intelligence and machine learning to advance drug discovery and development. Through collaborations with leading research institutions, BullFrog AI uses causal AI in combination with its proprietary bfLEAP™ platform to analyze complex biological data, aiming to streamline therapeutics development and reduce failure rates in clinical trials.

For more information visit BullFrog AI at: https://bullfrogai.com

About Sygnature Discovery

Sygnature Discovery is a world-leading integrated drug discovery contract research organization based in the UK and Canada with headquarters in Nottingham (UK). Additional sites are located in Alderley Park, Macclesfield, and Glasgow (UK), as well as Montreal and Quebec City (Canada). Its team of over 1,000 employees, which includes 900 scientists, partners with global biotech, pharma and NFP organizations. Since 2011, Sygnature Discovery has delivered 56 novel pre-clinical and 35 clinical compounds, with its scientists named on over 235 patents. Therapeutic areas of expertise include oncology, inflammation and immunology, neuroscience, metabolic diseases, infectious diseases, fibrotic diseases, and more.

Safe Harbor Statement

This press release contains forward-looking statements. We base these forward-looking statements on our expectations and projections about future events, which we derive from the information currently available to us. Such forward-looking statements relate to future events or our future performance, including: our financial performance and projections; our revenue and earnings; and our business prospects and opportunities. You can identify forward-looking statements by those that are not historical in nature, particularly those that use terminology such as "may," "should," “could,” “will,” "expects," "anticipates," "contemplates," "estimates," "believes," "plans," "projected," "predicts," "potential," or "hopes" or the negative of these or similar terms. In evaluating these forward-looking statements, you should consider various factors, including: our ability to change the direction of the Company; our ability to keep pace with new technology and changing market needs; our and our partners’ ability to market and sell our offerings and services, including BullFrog Data Networks™ and the competitive environment of our business. In particular, there can be no assurance as to the actual revenues to be received from this collaboration, which are subject to a number of factors and risks, such as Sygnature’s ability to effectively sell BullFrog Data Networks™ to its clients. These and other factors may cause our actual results to differ materially from any forward-looking statement. Forward-looking statements are only predictions. The forward-looking events discussed in this press release and other statements made from time to time by us or our representatives, may not occur, and actual events and results may differ materially and are subject to risks, uncertainties, and assumptions about us. We are not obligated to publicly update or revise any forward-looking statement, whether as a result of uncertainties and assumptions, the forward-looking events discussed in this press release and other statements made from time to time by us or our representatives might not occur.

Contact:

Dave Gentry
RedChip Companies, Inc.
1-407-644-4256
BFRG@redchip.com

FAQ

What is the potential revenue opportunity for BullFrog AI's (BFRG) partnership with Sygnature Discovery?

The partnership represents a revenue opportunity estimated at $15-30 million through 2028.

When did BullFrog AI (BFRG) officially launch BullFrog Data Networks sales?

The formal sales kickoff occurred on September 12, 2025, following the completion of Sygnature's business development team training.

What are the main applications of BullFrog AI's (BFRG) Data Networks platform?

The platform is used for early target identification, mechanism-of-action elucidation, patient stratification, drug repurposing, and clinical trial optimization.

How will Sygnature Discovery distribute BullFrog AI's (BFRG) platform?

Sygnature Discovery will market BullFrog Data Networks™ as part of their drug discovery solutions portfolio to their global biopharma client base.

What makes BullFrog AI's (BFRG) Data Networks platform unique for drug development?

The platform uses AI and machine learning to help researchers navigate complex, multi-modal datasets and uncover hidden relationships critical to understanding disease biology.